Țară: Statele Unite ale Americii
Limbă: engleză
Sursă: NLM (National Library of Medicine)
PAROXETINE HYDROCHLORIDE HEMIHYDRATE (UNII: X2ELS050D8) (PAROXETINE - UNII:41VRH5220H)
Solco Healthcare US, LLC
PAROXETINE HYDROCHLORIDE HEMIHYDRATE
PAROXETINE 10 mg
ORAL
PRESCRIPTION DRUG
Major Depressive Disorder: Paroxetine Tablets are indicated for the treatment of major depressive disorder. The efficacy of Paroxetine Tablets in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The effects of Paroxetine Tablets in hospitalized depressed patients have not been adequately studied.
Tablets: Film-coated, capsule-shaped as follows: Paroxetine Tablets USP, 10-mg beige to light brown, scored tablets, debossed with ‘710’ on one side and ‘HH’ on the other side with the score line in between. NDC 43547-347-03 Bottles of 30 NDC 43547-347-09 Bottles of 90 NDC 43547-347-50 Bottles of 500 NDC 43547-347-11 Bottles of 1000 Paroxetine Tablets USP, 20-mg beige to light brown, scored tablets, debossed with ‘711’ on one side and ‘HH’ on the other side with the score line in between. NDC 43547-348-03 Bottles of 30 NDC 43547-348-09 Bottles of 90 NDC 43547-348-50 Bottles of 500 NDC 43547-348-11 Bottles of 1000 The above 10 mg and 20 mg strength tablets are functionally scored, each can be split into two halves. Paroxetine Tablets USP, 30-mg beige to light brown tablets, debossed with ‘712’ on one side and ‘HH’ on the other side. NDC 43547-349-03 Bottles of 30 NDC 43547-349-09 Bottles of 90 NDC 43547-349-50 Bottles of 500 NDC 43547-349-11 Bottles of 1000 Paroxetine Tablets USP, 40-mg beige to light brown tablets, debossed with ‘713’ on one side and ‘HH’ on the other side. NDC 43547-350-03 Bottles of 30 NDC 43547-350-09 Bottles of 90 NDC 43547-350-50 Bottles of 500 NDC 43547-350-11 Bottles of 1000 Store tablets at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] You may report side effects to Solco Healthcare US, LLC at 1-866-257-2597 or FDA at 1-800-FDA-1088. Manufactured by: Zhejiang Huahai Pharmaceutical Co., Ltd. Xunqiao, Linhai, Zhejiang 317024, China Distributed by: Solco Healthcare US, LLC. Somerset, NJ 08873, USA Revise Date: 08/2020 200202-01
Abbreviated New Drug Application
PAROXETINE- paroxetine hydrochloride hemihydrate tablet, film coated Solco Healthcare US, LLC ---------- Medication Guide Paroxetine Tablets USP (PA-rox-eh-tine) Read the Medication Guide that comes with Paroxetine Tablets before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. Talk with your healthcare provider if there is something you do not understand or want to learn more about. What is the most important information I should know about Paroxetine Tablets? Paroxetine Tablets and other antidepressant medicines may cause serious side effects, including: 1. Suicidal thoughts or actions: • Paroxetine Tablets and other antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment or when the dose is changed. • Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions. • Watch for these changes and call your healthcare provider right away if you notice: • New or sudden changes in mood, behavior, actions, thoughts, or feelings, especially if severe. • Pay particular attention to such changes when Paroxetine Tablets are started or when the dose is changed. Keep all follow-up visits with your healthcare provider and call between visits if you are worried about symptoms. Call your healthcare provider right away if you have any of the following symptoms, or call 911 if an emergency, especially if they are new, worse, or worry you: • attempts to commit suicide • acting on dangerous impulses • acting aggressive or violent • thoughts about suicide or dying • new or worse depression • new or worse anxiety or panic attacks • feeling agitated, restless, angry, or irritable • trouble sleeping • an increase in activity or talking more than what is normal for you • other unusual changes in behavior or m Citiți documentul complet
PAROXETINE- PAROXETINE HYDROCHLORIDE HEMIHYDRATE TABLET, FILM COATED SOLCO HEALTHCARE US, LLC ---------- PAROXETINE TABLETS USP, FILM COATED FOR ORAL USE SUICIDALITY AND ANTIDEPRESSANT DRUGS ANTIDEPRESSANTS INCREASED THE RISK COMPARED TO PLACEBO OF SUICIDAL THINKING AND BEHAVIOR (SUICIDALITY) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS IN SHORT-TERM STUDIES OF MAJOR DEPRESSIVE DISORDER (MDD) AND OTHER PSYCHIATRIC DISORDERS. ANYONE CONSIDERING THE USE OF PAROXETINE TABLETS OR ANY OTHER ANTIDEPRESSANT IN A CHILD, ADOLESCENT, OR YOUNG ADULT MUST BALANCE THIS RISK WITH THE CLINICAL NEED. SHORT-TERM STUDIES DID NOT SHOW AN INCREASE IN THE RISK OF SUICIDALITY WITH ANTIDEPRESSANTS COMPARED TO PLACEBO IN ADULTS BEYOND AGE 24; THERE WAS A REDUCTION IN RISK WITH ANTIDEPRESSANTS COMPARED TO PLACEBO IN ADULTS AGED 65 AND OLDER. DEPRESSION AND CERTAIN OTHER PSYCHIATRIC DISORDERS ARE THEMSELVES ASSOCIATED WITH INCREASES IN THE RISK OF SUICIDE. PATIENTS OF ALL AGES WHO ARE STARTED ON ANTIDEPRESSANT THERAPY SHOULD BE MONITORED APPROPRIATELY AND OBSERVED CLOSELY FOR CLINICAL WORSENING, SUICIDALITY, OR UNUSUAL CHANGES IN BEHAVIOR. FAMILIES AND CAREGIVERS SHOULD BE ADVISED OF THE NEED FOR CLOSE OBSERVATION AND COMMUNICATION WITH THE PRESCRIBER. PAROXETINE TABLETS ARE NOT APPROVED FOR USE IN PEDIATRIC PATIENTS. (SEE WARNINGS: CLINICAL WORSENING AND SUICIDE RISK, PRECAUTIONS: INFORMATION FOR PATIENTS, AND PRECAUTIONS: PEDIATRIC USE.) DESCRIPTION Paroxetine hydrochloride is an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as _(-)-trans_-_4R_- (4'_-_fluorophenyl)-_3S_-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate and has the empirical formula of C H FNO •HCl•1/2H O. The molecular weight is 374.8 (329.4 as free base). The structural formula of paroxetine hydrochloride is: Paroxetine hydrochloride, USP is an odorless, off-white powder, having a melting point range of 120° to 138°C and a solubility of 5.4 mg/mL in water. TABLETS: Citiți documentul complet